

Novel device therapies: "Subcutaneous, Leadless, and his Bundle and more"



Paul A. Friedman, MD Mayo Clinic Rochester, MN USA

Evolution of Pacemakers

CENTRAL ILLUSTRATION An Overview of the History of Cardiac Pacing

Paradigm Shifts in Cardiac Pacemakers

1950s

AC-powered pacemakers tethered to an extension cord (Furman)



1950s

Battery-powered transistorized "wearable" pacemakers (Lillehei/Bakken)



1958

First fully implantable pacemaker (Elmqvist/ Senning)



2015

Implantable pacemaker basic system had not evolved significantly



Fundamental
Paradigm
Hasn't
changed for
50 years!
Now many
new
approaches



Leads and Tricuspid Regurgitation








Photo courtesy of W. Edwards, MD Dept. Pathology, Mayo Clinic

Photo courtesy of Dr Sundt Mayo Clinic, CV Surgery


Stroke Risk with PFO and Transvenous Leads






Mobile thrombi: 30% leads on intracardiac imaging


Right Ventricular Apical Pacing: Increased Mortality, Heart Failure, Hospitalizations, AF






Pacing the RV induces a LBBB pattern—that delays lateral wall activation.







The Revolution in Cardiac Implantable Electronic Devices Extravascular or minimally vascular Devices SICD **EV-ICD** Leadless PM Physiologic devices: His Bundle pacing/LB **Endocardial LV pacing CCM**





Patient with LBBB, low EF, CRT lead cannot be placed






Patient with LBBB, low EF, CRT lead cannot be placed






Resynchronization: Two sites vs. Thousands







Tawara









Selective His Pacing


 Stim-QRS = native His-QRS (depending on lead position and if normal HP conduction)


Local V EGM not directly captured (S-V = H-V); difference usually < 10 msec

QRS same as native (if nl)

Usually: single capture threshold


 At high output may have non-selective pacing (fusion)







RV Pacing vs. His Bundle Pacing




 Non-randomized, two different hospitals, showed promise for Long term HBP

His-bundle pacing: impact of social media


Dominik Beer¹, Gopi Dandamudi², John M. Mandrola³, Paul A. Friedman⁴, and Pugazhendhi Vijayaraman (D) ¹*


Europace (2019) 21, 1445–1450 doi:10.1093/europace/euz169





Meta-analysis: 26 studies, 1438 patients






Amongst 26 studies, the implant success rate averaged 84.8% and LVEF improved by an average of 5.9% during follow-up. Them mean threshold was 1.8V, varying pulse width. There is a need for uniformity.




Pacing at Site of Thin Tissue and Proximal Conduction




- Thresholds are higher (up to 20% fail implant, 30% rise post implant)
- R waves smaller
- Dislodgment risk greater (8%)
- Autocapture thresholds / threshold more difficult

We found the His Bundle...CHB






LBBB pacing






Testing LB Pacing





New Electrical Device Therapies for CHF

- His Bundle pacing
- Leaded Endocardial CRT
- Leadless Endocardial CRT
- Cardiac Contraction Modulation




Pace here instead of His

- Physiologic
- · ?easier
- Lower risk of block




Multicenter prospective observational long-term follow-up study of endocardial cardiac resynchronization therapy using the Jurdham procedure © • Heart Rhythm 2019;16:1453-1461

Benjamin Elencwajg, MD,*^{†‡} Néstor López-Cabanillas, MD,*^{†‡} Avi Fischer, MD, FHRS,*^{†‡} Alberto Negrete, MD,[§] Jorge Marin, MD,[¶] Lorena Delgado, MD,*^{†‡} Michael Glikson, MD, FHRS,^{||} Luis Molina, MD,** Seth Worley, MD, FHRS,^{††} Jaime Arnez, MD,^{‡‡} Fernando Vidal, MD,^{§§} Paul A. Friedman, MD, FHRS,^{¶¶} on behalf of the Jurdham Group






JURDHAM Procedure






Endocardial LV CRT: Jurdham Procedure EP developed without industry support






Endocardial CRT (eCRT)





Ejection Fraction response to eCRT



88 patients; 72% failed CRT 80% NYHA III; 10% NYHA IV Implant success 100%; FC: NYHA 2.9→1.3




Endocardial LV Summary

- Remarkable response rate to eCRT -- >80% super-responders (Jurdham)
- Feasible with off the shelf tools, widely disseminated, in resource constrained environments
- Risk of stroke/TIA remains incompletely resolved issue
 - Balance with risk of CHF death/stroke
- For patients who must be anticoagulated, may be an attractive option




Rx: ASA + Clopidogre x 3 mo → ASA





Endocardial LV pacing






Endocardial LV Ultrasound system


- Appears very effective (as does endo-CRT)
- Likely low risk CVA
- Very promising specially for CRT failures

- But:
 - Two stage implant technique, over two days
 - Two batteries, and ?s about battery longevity
 - Data are pending clinical study ongoing
 - Long-term chronic US stim?



Cardiac Contraction Modulation only option for <u>narrow QRS</u> (<130)





Thank you


• pfriedman@mayo.edu








CCM Mechanisms





CCM Mechanisms

- Gene expression (Ca++): changes within 2 hours at site of electrodes
- Local and remote gene expression changes: within 3 months
- Revions from fetal phenotype towards normal adult, with improve Ca++ handling
 - Upregulation of SERCA
 - Phosphorylation: phospholamban
 - Improved Ca++ updake SR





Functional Improvement to eCRT

